SVRA - Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? | Benzinga
The latest trial study from Savara Inc (NASDAQ:SVRA) met its primary endpoint.
The company released results from Phase 3 IMPALA-2 trial of molgramostim 300 mcg administered once daily by inhalation with a matching placebo for autoimmune pulmonary alveolar proteinosis (aPAP).
Matt Pauls, CEO Savara, praised the results.
PAP is a rare lung disease caused by a buildup of proteins, fats, and other substances in the lungs’ air sacs (alveoli).
Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
The treatment difference between molgramostim and placebo for mean change from baseline to Week 24 in hemoglobin-adjusted percent ...